{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:40:42Z","timestamp":1778276442684,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.mayocp.2015.05.011","type":"journal-article","created":{"date-parts":[[2015,7,10]],"date-time":"2015-07-10T00:41:27Z","timestamp":1436488887000},"page":"1030-1037","source":"Crossref","is-referenced-by-count":39,"title":["Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease"],"prefix":"10.1016","volume":"90","author":[{"given":"Marie C.","family":"Hogan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetyana","family":"Masyuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Bergstralh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bill","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter K.","family":"Kremers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa E.","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Ihrke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda L.","family":"Severson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria V.","family":"Irazabal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Glockner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas F.","family":"LaRusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mayocp.2015.05.011_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2215\/CJN.00080605","article-title":"Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort","volume":"1","author":"Bae","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.mayocp.2015.05.011_bib2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.mayocp.2015.05.011_bib3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2215\/CJN.05380709","article-title":"Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide","volume":"5","author":"Caroli","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.mayocp.2015.05.011_bib4","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.mayocp.2015.05.011_bib5","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.mayocp.2015.05.011_bib6","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: results after 2 years","volume":"27","author":"Hogan","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"9903","key":"10.1016\/j.mayocp.2015.05.011_bib7","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.mayocp.2015.05.011_bib8","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1136\/gut.2008.155721","article-title":"Somatostatin analogues reduce liver volume in polycystic liver disease","volume":"57","author":"van Keimpema","year":"2008","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.mayocp.2015.05.011_bib9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","article-title":"The long-term outcome of patients with polycystic liver disease treated with lanreotide","volume":"35","author":"Chrispijn","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.mayocp.2015.05.011_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11255-010-9748-1","article-title":"Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease","volume":"43","author":"Peces","year":"2011","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"10.1016\/j.mayocp.2015.05.011_bib11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000358268","article-title":"The use of lanreotide in polycystic kidney disease: a single-centre experience","volume":"4","author":"Treille","year":"2014","journal-title":"Case Rep Nephrol Urol"},{"issue":"7","key":"10.1016\/j.mayocp.2015.05.011_bib12","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2215\/CJN.01870309","article-title":"Cyst infections in patients with autosomal dominant polycystic kidney disease","volume":"4","author":"Sallee","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"20","key":"10.1016\/j.mayocp.2015.05.011_bib13","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.mayocp.2015.05.011_bib14","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2015.05.011_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.ajkd.2013.12.013","article-title":"Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP)","volume":"64","author":"Haynes","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"6842","key":"10.1016\/j.mayocp.2015.05.011_bib16","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1136\/bmj.304.6842.1611","article-title":"Effects of long term octreotide on gall stone formation and gall bladder function","volume":"304","author":"Bigg-Wither","year":"1992","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.mayocp.2015.05.011_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1365-2265.1998.00389.x","article-title":"Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly","volume":"48","author":"Davies","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1016\/j.mayocp.2015.05.011_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.7326\/0003-4819-112-3-173","article-title":"Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly: effects of dose and frequency and long-term safety","volume":"112","author":"Ho","year":"1990","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.mayocp.2015.05.011_bib19","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0025-6196(12)65154-4","article-title":"Hepatic cyst infection in autosomal dominant polycystic kidney disease","volume":"65","author":"Telenti","year":"1990","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.mayocp.2015.05.011_bib20","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1093\/ndt\/gfs352","article-title":"Diagnosis of cyst infection in patients with autosomal dominant polycystic kidney disease: attributes and limitations of the current modalities","volume":"27","author":"Jouret","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.mayocp.2015.05.011_bib21","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/ndt\/gfu227","article-title":"Diagnostic criteria in renal and hepatic cyst infection","volume":"30","author":"Lantinga","year":"2015","journal-title":"Nephrol Dial Transplant"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619615004279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619615004279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T21:53:10Z","timestamp":1537480390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619615004279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0025619615004279"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2015.05.011","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}